个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Zhou, Q.[1] * ; Meng, X.[2] ; Sun, L.[3] ; Huang, D.[4] ; Yang, N.[5] ; Yu, Y.[6] ; Zhao, M.[7] ; Zhuang, W.[8] ; Hu, Y.[9] ; Pan, Y.[10] ; Sun, M.[11] ; Shan, J.[12] ; Guo, R-H.[13] ; Chu, Q.[14] ; Xu, C.[1] ; Lin, J.[1] ; Huang, J.[15] ; Huang, M.[16] ; Shen, Y.[15] ; Wu, Y-L.[1] ;
单位： [1]Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China [2]Shandong First Med Univ, Affiliated Canc Hosp, Radiotherapy Dept, Jinan, Peoples R China [3]Nanchang Univ, Affiliated Hosp 1, Resp Dept, Nanchang, Jiangxi, Peoples R China [4]Tianjin Med Univ, Canc Inst & Hosp, Dept Pulm Oncol, Tianjin, Peoples R China [5]Hunan Canc Hosp, Dept Pulm Gastroenterol, Changsha, Peoples R China [6]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [7]China Med Univ, Affiliated Hosp 1, Med Oncol Ward 2, Shenyang, Peoples R China [8]Fujian Canc Hosp, Dept Med Oncol, Fuzhou, Peoples R China [9]Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Med Oncol, Beijing, Peoples R China [10]Anhui Prov Hosp, Dept Tumor Chemotherapy, Hefei, Peoples R China [11]Shandong First Med Univ, Cent Hosp, Dept Oncol, Jinan, Peoples R China [12]Army Specialty Med Ctr PLA, Dept Oncol, Chongqing, Peoples R China [13]Jiangsu Prov Hosp, Oncol Dept, Nanjing, Peoples R China [14]Tongji Hosp, Tongji Med Coll Hust, Dept Thorac Oncol, Wuhan, Peoples R China [15]Innovent Biol Inc, Dept Med Sci & Oncol, Suzhou, Peoples R China [16]Innovent Biol Inc, Dept Biostat & Informat Sci, Suzhou, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.10.584
ISSN：
基金：
Innovent Biologics, Inc., Suzhou, China
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou Q.,Meng X.,Sun L.,et al.Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study[J].ANNALS OF ONCOLOGY.2023,34:S1662-S1662.doi:10.1016/j.annonc.2023.10.584.
APA：
Zhou, Q.,Meng, X.,Sun, L.,Huang, D.,Yang, N....&Wu, Y-L..(2023).Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study.ANNALS OF ONCOLOGY,34,
MLA：
Zhou, Q.,et al."Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study".ANNALS OF ONCOLOGY 34.(2023):S1662-S1662

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）